Kurzfassung

Phase 3, randomized, double-blind, active-controlled study evaluating Momelotinib vs. Ruxolitinib in subjects with primary myelofibrosis (PMF) or post-polycythemia vera or post- essential thrombocythemia myelofibrosis (Post-PV/ET MF)